We are excited to inform the cat-loving public and veterinary professionals that Stokes Pharmacy, working in collaboration with the Bova Group, announced on 5/30/24 that it will be making a compounded oral formulation of GS-441524 available for the treatment of feline infectious peritonitis (FIP) in the United States which became available on June 1st, 2024. 

Considered an almost routinely fatal disease until the development of this unique compound in 2018, GS-441524 has been shown to be a safe and effective therapy for the treatment of FIP in cats in a number of clinical trials carried out primarily in Australia and the UK.

The fact that this compound was not previously FDA - approved prompted many understandably desperate U.S. owners of FIP-infected cats to seek it through unregulated and often unreliable black-market sources for several years. This announcement, combined with the fact that the FDA’s Center for Veterinary Medicine (CVM) has notified veterinarians that compounded GS-441524 falls under Guidance for Industry #256 and is allowed to be compounded and legally prescribed, provides a significant ray of hope in treating a previously untreatable and devastating feline disease.

Initially developed as an injectable drug, the transition to an oral formulation represents an important step in making GS-441524 a more feasible treatment modality for most cat owners.

A veterinary prescription will be required to obtain GS-441524 therapy for an FIP-infected cat, and we recommend that you consult with your veterinarian if you have any questions about how to obtain this game-changing novel therapy.

You can find out more about this exciting news here and we will be sure to update the cat loving public about any new developments on this front as soon as we become aware of them.

Cornell Feline Health Center Webinar: Feline Infectious Peritonitis (FIP) treatment in the USA